21-hydroxylase deficiency secondary prevention: Difference between revisions
No edit summary |
Aditya Ganti (talk | contribs) |
||
| Line 21: | Line 21: | ||
[[Category:Intersexuality]] | [[Category:Intersexuality]] | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Up-To-Date]] | [[Category: Up-To-Date]] | ||
Latest revision as of 15:27, 24 July 2020
|
21-hydroxylase deficiency Microchapters |
|
Differentiating 21-Hydroxylase Deficiency from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
21-hydroxylase deficiency secondary prevention On the Web |
|
American Roentgen Ray Society Images of 21-hydroxylase deficiency secondary prevention |
|
Risk calculators and risk factors for 21-hydroxylase deficiency secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
Continued monitoring of hormone balance and careful readjustment of glucocorticoid dose is helpful in controlling fertility and preventing adrenal crisis in patient with 21-hydroxylase deficiency.
Secondary Prevention
Preventing hyperandrogenism and optimizing fertility
Continued monitoring of hormone balance and careful adjustment of glucocorticoid dose is helpful in controlling infertility. In general, women with 21-hydroxylase deficiency have a lower fertility rate.[1]
Preventing adrenal crisis
To prevent adrenal crisis, all patients taking glucocorticoids replacement should take bolus dose of glucocorticoids during severe illness, surgery and severe exhaustion.
References
- ↑ Mnif MF, Kamoun M, Kacem FH, Mnif F, Charfi N, Naceur BB, Rekik N, Abid M (2013). "Reproductive outcomes of female patients with congenital adrenal hyperplasia due to 21-hydroxylase defi ciency". Indian J Endocrinol Metab. 17 (5): 790–3. doi:10.4103/2230-8210.117196. PMC 3784860. PMID 24083158.